Nearly 30% of revenue from reversible contraceptive devices in the US will be lost in 2020 due to COVID-19, as many procedures have been postponed and clinics have been closed. In comparison, developing countries are expected to experience a less severe decline, as governments have previously dealt with providing reproductive health during pandemics such as Ebola, according to GlobalData, a leading data and analytics company.

Eric Chapman, Medical Devices Analyst at GlobalData, says: “GlobalData estimates an overall reduction of 28.9% of revenue for reversible contraceptive devices in the US by the end of 2020, compared to previous forecasts before the outbreak of SARS-COV2. In Q1 2020, elective procedures were postponed in the country from around mid-March (two out of 12 weeks), resulting in a decline of around 12.5% of revenue. Q2 2020 was the worst quarter for the market, as the first peak of new COVID-19 cases occurred in April and many procedures had been cancelled or postponed. As a result, the market was down approximately 73.2%.”

“In Q3 2020, GlobalData estimates that the market will begin to experience a gradual recovery as clinics begin to reopen and procedures are rescheduled. Initially, GlobalData estimated an overall reduction of 30% of revenue for the quarter, compared to predictions before the COVID-19 outbreak – however, a resurgence of new COVID-19 cases in regions such as the South and South West might result in clinics once again shutting their doors and further delays in procedures.

“By Q4 2020, GlobalData anticipates the start of a ‘surge period’ for the reversible contraceptive devices market, to make up for procedures that were postponed earlier in the year. However, this surge will not be enough to offset revenue losses until the end of 2021 or early 2022.”

For more information, send your questions to Rebecca Panks, PR Executive at GlobalData (pr@globaldata.com)